957a7228-3558-48fd-81d9-13f951e0b597
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.600
- COMPLEMENT+0.500
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- IL2_STAT5_SIGNALING+0.400
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- DNA_REPAIR-0.300
- MYC_TARGETS_V1-0.100
- BILE_ACID_METABOLISM+0.000
- GLYCOLYSIS+0.000
- KRAS_SIGNALING_DN+0.000
- MYOGENESIS+0.000
- NOTCH_SIGNALING+0.000
- OXIDATIVE_PHOSPHORYLATION+0.000
- P53_PATHWAY+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290947 | — | — | 0.904 |
| 2 | BS_0SCXXM6N | low-grade glioma | — | 0.886 |
| 3 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.885 |
| 4 | DRR168605 | — | — | 0.870 |
| 5 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.863 |
| 6 | SRR934980 | — | — | 0.861 |
| 7 | SRR10899973 | — | — | 0.861 |
| 8 | SRR35579823 | — | D | 0.857 |
| 9 | TCGA-AR-A24U-01A-11R-A169-07 | — | C | 0.853 |
| 10 | SRR5088852 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.600 | Idelalisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |